Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
Abstract Purpose: To update the American Society of Clinical Oncology (ASCO)/American
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Myelodysplastic syndromes
L Adès, R Itzykson, P Fenaux - The Lancet, 2014 - thelancet.com
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
Soluble transferrin receptor for the evaluation of erythropoiesis and iron status
Y Beguin - Clinica chimica acta, 2003 - Elsevier
Iron transport in the plasma is carried out by transferrin, which donates iron to cells through
its interaction with a specific membrane receptor, the transferrin receptor (TfR). A soluble …
its interaction with a specific membrane receptor, the transferrin receptor (TfR). A soluble …
Erythropoietin or darbepoetin for patients with cancer
T Tonia, A Mettler, N Robert… - Cochrane database …, 2012 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
P Valent, HP Horny, JM Bennett, C Fonatsch… - Leukemia research, 2007 - Elsevier
The classification, scoring systems, and response criteria for myelodysplastic syndromes
(MDS) have recently been updated and have become widely accepted. In addition, several …
(MDS) have recently been updated and have become widely accepted. In addition, several …
Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly …
P Wijermans, M Lubbert, G Verhoef, A Bosly… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that
has shown a 50% response rate in a small phase II study in elderly patients with high-risk …
has shown a 50% response rate in a small phase II study in elderly patients with high-risk …
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
A Raza, JA Reeves, EJ Feldman… - Blood, The Journal …, 2008 - ashpublications.org
Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to
low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a …
low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a …
Myelodysplasia
ML Heaney, DW Golde - New England Journal of Medicine, 1999 - Mass Medical Soc
The myelodysplastic syndromes are clonal hematologic disorders characterized clinically
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
[HTML][HTML] Myelodysplastic syndromes: moving towards personalized management
E Hellström-Lindberg, M Tobiasson, P Greenberg - Haematologica, 2020 - ncbi.nlm.nih.gov
The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but
have otherwise very heterogeneous biological and genetic characteristics. Clinical features …
have otherwise very heterogeneous biological and genetic characteristics. Clinical features …